Keyword: Vasant Narasimhan
Novartis’ prospects for launching a copy of GlaxoSmithKline’s Advair this year just went from highly unlikely to not happening.
Novartis investors' discontent with first-quarter results shows how much they're expecting of new CEO Vas Narasimhan.
Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.
A long list of biopharma materials and medical devices from China have become targets of additional U.S. tariffs.
A prosecutor in Greece who is investigating bribery allegations against Novartis is probing the financial assets of more than 30 former politicians.
Novartis rejigged its exec team to further big ambitions for digital tech, tighten up compliance and replace its head of operations.
Putting digital into Novartis' DNA is one of CEO Vas Narasimhan’s goals, and the drugmaker has just inked another deal that aims to do just that.
Novartis and Bayer executives were among a list of attendees at a private dinner in Davos with U.S. President Donald Trump.
Just months after picking up Advanced Accelerator Applications, Novartis is getting a quick boost with the U.S. approval for Lutathera.
Incoming Novartis chief Vas Narasimhan outlined his big goals as CEO on Wednesday: Think drug launches and more drug launches.